Language：English   Publishing type：Research paper (scientific journal)  

The main symptom in primary syphilis is a small, painless, sore or ulcer called a chancre on the penis, vagina, or around the anus, although chancres can sometimes appear in the mouth or on the lips, fingers, or buttocks. We present the case of a man in his early 60 s with a chief complaint of a painful tongue ulcer. An ulcerated, indurated, and hemorrhagic lesion (23 × 14 mm) was found on the ventral tongue surface, near the oral floor. Palpation identified several swollen, mobile, elastic cervical lymph nodes, with no tenderness. We initially diagnosed tongue cancer; however, during a subsequent detailed examination for a malignant tumor, including biopsy and obtaining additional history, his disease was finally identified as primary syphilis with multiple swollen cervical lymph nodes. Oral amoxicillin and probenecid were started, and after 14 days, there was partial reduction in the size of the submandibular lymph nodes and the ulcer on the left tongue margin. The number of patients with syphilis in Japan increased by eight times from 2012 to 2018. We suggest that dentists consider primary syphilis as a differential diagnosis for oral refractory ulcer with induration and obtain a detailed patient history.

DOI： 10.1177/03000605231161223

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本口腔診断学会  

researchmap

Language：Japanese   Publisher：日本口腔組織培養学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Mutations in p53 are common in human oral squamous cell carcinoma (OSCC). However, in previous analyses, only detection of mutant p53 protein using immunohistochemistry or mutations in some exons have been examined. Full length mutant p53 protein in many cases shows a loss of tumor suppressor function, but in some cases possibly shows a gain of oncogenic function. In this study, we investigate relationships of outcomes with the mutational spectrum of p53 (missense and truncation mutations) in whole exon in OSCC. Specimens from biopsy or surgery (67 cases) were evaluated using next-generation sequencing for p53, and other oncogenic driver genes. The data were compared with overall survival (OS) and disease-free survival (DFS) using univariate and multivariate analyses. p53 mutations were detected in 54 patients (80.6%), 33 missense mutations and 24 truncation mutations. p53 mutations were common in the DNA-binding domain (43/52) and many were missense mutations (31/43). Mutations in other regions were mostly p53 truncation mutations. We detected some mutations in 6 oncogenic driver genes on 67 OSCC, 25 in NOTCH1, 14 in CDKN2A, 5 in PIK3CA, 3 in FBXW7, 3 in HRAS, and 1 in BRAF. However, there was no associations of the p53 mutational spectrum with mutations of oncogenic driver genes in OSCC. A comparison of cases with p53 mutations (missense or truncation) with wild-type p53 cases showed a significant difference in lymph node metastasis. DFS was significantly poorer in cases with p53 truncation mutations. Cases with p53 truncation mutations increased malignancy. In contrast, significant differences were not found between cases with p53 missense mutations and other mutations. The p53 missense mutation cases might include cases with mostly similar function to that of the wild-type, cases with loss of function, and cases with various degrees of gain of oncogenic function.

DOI： 10.1038/s41598-022-25744-8

PubMed

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：(一社)日本小児口腔外科学会  

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

DOI： 10.1016/j.ajoms.2021.10.011

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

researchmap

Language：Japanese   Publisher：(一社)栃木県歯科医師会  

当科における最新の口腔癌の診断・治療方針をまとめ、それらに伴う治療状況について臨床統計学的検討を行った。当科における口腔癌治療は根治性を重視して、年齢問わずStage 4bまでは切除可能と考え、積極的に外科治療を適用している。2007年～2020年の当科における口腔扁平上皮癌1次手術症例324例を検討すると、非高齢者・准高齢者・高齢者の間で5年累積生存率(OS)、5年累積無病率(DFR)は有意差は認めず、高齢が外科的治療回避の基準にはならないことが示された。major risk群ではOS・DFRの有意な低下が認められ、術後のリスク評価としてmajor risk factorの有用性、またmajor risk患者へのcetuximabの有効性が示唆された。

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

researchmap

Language：Japanese   Publisher：(一社)日本有病者歯科医療学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The surveillance methods oral squamous cell carcinoma (OSCC) patients may be chosen by considering the risk for recurrence, and it is important to establish appropriate methods during the period in which latent/dormant cancer cells become more apparent. To investigate the appropriate surveillance of patients with OSCC based on the individual risk for recurrence and/or metastasis, we performed a retrospective cohort study after the complete surgical resection of OSCC as the primary treatment. METHODS: The study was performed in 324 patients with OSCC who had been primarily treated with surgery from 2007 to 2020 at our hospital. We investigated the period, timing, and methods (visual examination, palpation and imaging using FDG-PET/CT or CECT) for surveillance in each case that comprised postsurgical treatment. RESULTS: Regarding the time to occurrence of postsurgical events, we found that half of cases of local recurrence, cervical lymph node metastasis, and distant metastasis occurred within 200 days, and 75% of all of these events occurred within 400 days. However, the mean time for second primary cancer was 1589 days. The postsurgical events were detected earlier by imaging examinations than they were by visual examination and palpation. CONCLUSIONS: For the surveillance of patients with OSCC after primary surgery, it is desirable to perform FDG-PET/CT within 3-6 months and at 1 year after surgery and to consider CECT as an option in between FDG-PET/CT, while continuing history and physical examinations for about 5 years based on individual risk assessment.

DOI： 10.3390/cancers13225843

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本有病者歯科医療学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：{MDPI} {AG}  

TSC-22 (TGF-β stimulated clone-22) has been reported to induce differentiation, growth inhibition, and apoptosis in various cells. TSC-22 is a member of a family in which many proteins are produced from four different family genes. TSC-22 (corresponding to TSC22D1-2) is composed of 144 amino acids translated from a short variant mRNA of the TSC22D1 gene. In this study, we attempted to determine the intracellular localizations of the TSC22D1 family proteins (TSC22D1-1, TSC-22 (TSC22D1-2), and TSC22(86) (TSC22D1-3)) and identify the binding proteins for TSC22D1 family proteins by mass spectrometry. We determined that TSC22D1-1 was mostly localized in the nucleus, TSC-22 (TSC22D1-2) was localized in the cytoplasm, mainly in the mitochondria and translocated from the cytoplasm to the nucleus after DNA damage, and TSC22(86) (TSC22D1-3) was localized in both the cytoplasm and nucleus. We identified multiple candidates of binding proteins for TSC22D1 family proteins in in vitro pull-down assays and in vivo binding assays. Histone H1 bound to TSC-22 (TSC22D1-2) or TSC22(86) (TSC22D1-3) in the nucleus. Guanine nucleotide-binding protein-like 3 (GNL3), which is also known as nucleostemin, bound to TSC-22 (TSC22D1-2) in the nucleus. Further investigation of the interaction of the candidate binding proteins with TSC22D1 family proteins would clarify the biological roles of TSC22D1 family proteins in several cell systems.

DOI： 10.3390/ijms222010913

PubMed

researchmap

Language：Japanese   Publisher：獨協医学会  

薬剤関連顎骨壊死(以下,MRONJ)の治療では積極的に外科療法を推奨する報告が多くみられる一方,保存療法に関して有効性や治療成績を示した報告は少ない.われわれはMRONJ治療の現状について臨床統計学的に解析し,保存療法の治療効果と限界および外科療法への切り替え時期について検討を行った.対象は,2008年から2020年までに当科で治療を行ったMRONJ患者157例(男性44例,女性113例,平均年齢74歳)とした.保存療法と外科療法の治療効果比較では,保存療法の有効率(61.7%),治癒率(38.3%)に対し外科療法の有効率,治癒率はともに94.4%と有意に高い治療効果を示していた(P<0.001).単変量・多変量解析における有効/無効での比較では,初診時stageが,また治癒/未治癒の比較では,初診時stageと原疾患がそれぞれ治療効果と有意に相関していた.MRONJの初診時stageが保存療法の治療効果に有意に関連しており,初診時stage 0/1症例や骨粗鬆症症例に対しては早期の外科療法にこだわらず,保存療法単独でも治癒が期待できる可能性があると考えられた.その一方で,初診時stage 2/3や悪性腫瘍症例では最終的に外科療法の適用を考慮すべきであり,十分な保存療法を継続しながら外科療法の導入を適切に判断する必要があると考えられた.(著者抄録)

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publisher：(一社)日本癌学会  

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Molecules that demonstrate a clear association with the aggressiveness of oral squamous cell carcinoma (OSCC) have not yet been identified. The current study hypothesized that tumor cells in OSCC have three different origins: Epithelial stem cells, oral tissue stem cells from the salivary gland and bone marrow (BM) stem cells. It was also hypothesized that carcinomas derived from less-differentiated stem cells have a greater malignancy. In the present study, sex chromosome analysis by fluorescence in situ hybridization and/or microdissection PCR was performed in patients with OSCC that developed after hematopoietic stem cell transplantation (HSCT) from the opposite sex. OSCC from 3 male patients among the 6 total transplanted patients were considered to originate from donor-derived BM cells. A total of 2/3 patients had distant metastasis, resulting in a poor prognosis. In a female patient with oral potentially malignant disorder who underwent HSCT, there were 10.7% Y-containing cells in epithelial cells, suggesting that some epithelial cells were from the donor. Subsequently, gene expression patterns in patients with possible BM stem cell-derived OSCC were compared with those in patients with normally developed OSCC by microarray analysis. A total of 3 patients with BM stem cell-derived OSCC exhibited a specific pattern of gene expression. Following cluster analysis by the probes identified on BM stem cell-derived OSCC, 2 patients with normally developed OSCC were included in the cluster of BM stem cell-derived OSCC. If the genes that could discriminate the origin of OSCC were identified, OSCCs were classified into the three aforementioned categories. If diagnosis can be performed based on the origin of the cancer cells, a more specific therapeutic strategy may be implemented to improve prognosis. This would be a paradigm shift in diagnostic and therapeutic strategies for OSCC.

DOI： 10.3892/ol.2021.12431

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The status of oral cancer therapy in elderly patients in Japan, where ageing is rapidly progressing, may serve as a model for other countries with similar demographics. There is controversy over what kind of treatment should be applied and how aggressively it should be applied to very elderly patients who have exceeded the average life expectancy. Given that 85 years is approximately the overall Japanese life expectancy at birth, we considered a threshold of 85 years and hypothesized that the prognosis of oral squamous cell carcinoma (SCC) patients aged ≥85 years was not inferior to that of those < 85 years. The aim of the present study was to investigate the clinical characteristics, treatment methods, and prognoses of Japanese oral SCC patients aged ≥85 years. METHODS: A retrospective cohort study was performed. The data of patients with primary oral SCC (n = 358) from 2005 to 2018 in our institute were extracted from electronic medical records. A total of 358 patients with oral SCC were divided into two groups (≥85 years group [n = 26] and < 85 years group [n = 332]) based on the age threshold of 85 years at the first visit. Kaplan-Meier survival analyses and Cox proportional hazard models were used to analyse overall survival (OS) and hazard ratios (HRs) according to age group, treatment, and TNM classification. RESULTS: There was no difference in the 5-year OS rate between the ≥85 years and < 85 years groups (80.8% vs. 82.2%, P = 0.359). This finding was the same in the operative (94.7% vs. 85.8%, P = 0.556) and non-operative (42.9% vs. 33.2%, P = 0.762) groups, indicating that age did not affect prognosis. Mortality was lower in the operative group than in the non-operative group (adjusted HR: 0.276, 95% CI: 0.156-0.489, P < 0.001), suggesting that surgery is a superior method. However, non-surgical treatment was selected at a higher rate in the ≥85 years group (26.9% vs. 11.1%, P = 0.028). CONCLUSIONS: This study suggests the prognosis of ≥85-year-old patients was not inferior to that of < 85-year-old patients. We recommend that surgery as the first choice treatment for ≥85-year-old patients with oral SCC who can tolerate surgery should be performed.

DOI： 10.1186/s12877-020-01902-3

PubMed

researchmap

Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

DOI： 10.1016/j.ijom.2020.10.004

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Anticancer Research USA Inc.  

BACKGROUND/AIM: Odontogenic diseases are diagnosed based on clinical course, imaging, and histopathology. However, a definitive diagnosis is not always possible. PATIENTS AND METHODS: We analyzed whole exons of SMO, BRAF, PTCH1 and GNAS using next-generation sequencing (NGS) in 18 patients. RESULTS: Of the 6 patients with ameloblastoma, 2 patients had the same missense mutation in BRAF, and 1 patient with peripheral ameloblastoma had a missense mutation in PTCH1. Of the 7 patients with odontogenic keratocyst, 4 patients had a missense mutation in PTCH1, 2 patients had missense mutations in BRAF, and 1 patient had a missense mutation in SMO. The patient with odontoma had missense mutations in SMO, BRAF and PTCH1. One patient with cement-osseous dysplasia had missense mutations in SMO and PTCH1. The patient with adenomatoid odontogenic tumor had missense mutations in SMO. CONCLUSION: Whole exome sequencing of the above genes by NGS would be useful for the differential diagnosis of odontogenic diseases.

DOI： 10.21873/invivo.12159

PubMed

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publisher：(一社)日本癌学会  

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：{MDPI} {AG}  

Administration of cetuximab (C-mab) in combination with paclitaxel (PTX) has been used for patients with head and neck squamous cell carcinoma (SCC) clinically. In this study, we attempted to clarify the molecular mechanisms of the enhancing anticancer effect of C-mab combined with PTX on oral SCC cells in vitro. We used two oral SCC cells (HSC4, OSC19) and A431 cells. PTX alone inhibited cell growth in all cells in a concentration-dependent manner. C-mab alone inhibited the growth of A431 and OSC19 cells at low concentrations, but inhibited the growth of HSC4 cells very weakly, even at high concentrations. A combined effect of the two drugs was moderate on A431 cells, but slight on HSC4 and OSC19 cells. A low concentration of PTX enhanced the antibody-dependent cellular cytotoxicity (ADCC) induced by C-mab in all of the cells tested. PTX slightly enhanced the anticancer effect of C-mab in this ADCC model on A431 and HSC4 cells, and markedly enhanced the anticancer effect of C-mab on OSC19 cells. These results indicated that PTX potentiated the anticancer effect of C-mab through enhancing the ADCC in oral SCC cells.

DOI： 10.3390/ijms21176292

PubMed

researchmap

Language：Japanese   Publisher：(一社)栃木県歯科医師会  

主に泌尿器科領域で使用されているHo:YAGレーザーを用いて静脈奇形に対し焼灼療法を施行したところ、良好な治療成績を得たので報告した。2015年1月〜2019年6月に表在性の静脈奇形と診断された患者37名(男性18名、女性19名、平均67歳)を対象とした。Ho:YAGレーザーを2.5W、0.5Jの条件下に、局所麻酔後、病変部表面粘膜が白色に変化するまで非接触下に焼灼した。病変が深部におよびレーザー光の到達が困難な症例や、表面焼灼後、内部に液体成分の残留を触知した症例では、外焼灼と併用して組織内焼灼を行う複合焼灼法を施行した。37例全例で、術中・術後に異常出血や知覚障害、機能障害は認めず、34例で完治が得られた。大きさは3mmから30mm程度のものがあり、複数個あるものが6症例であった。そのうちの3例には再発を認め、2例については再焼灼を行い治癒が得られた。残りの1例に関しては、再焼灼を提示するも患者本人が希望せず経過観察を行っている。Ho:YAGレーザーによる静脈奇形の治療方法は、機能や知覚の温存が可能でかつ特別な止血や縫合処置も必要としないため、形態を損なわず審美的な面からもきわめて有用であると考えられた。

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：Japanese   Publisher：千葉医学会  

researchmap

Language：Japanese   Publisher：(一社)日本有病者歯科医療学会  

researchmap

Language：English   Publisher：(一社)日本癌治療学会  

researchmap

Language：English   Publisher：日本癌学会  

researchmap

Language：Japanese   Publisher：(一社)日本有病者歯科医療学会  

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：千葉医学会  

researchmap

Authorship：Lead author   Publisher：Wiley  

DOI： 10.1002/osi2.1066

researchmap

Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/osi2.1066

Language：Japanese   Publisher：(一社)栃木県歯科医師会  

主に泌尿器科領域で使用されているHo:YAGレーザーを用いて静脈奇形に対し焼灼療法を施行したところ、良好な治療成績を得たので報告した。2015年1月〜2019年6月に表在性の静脈奇形と診断された患者37名(男性18名、女性19名、平均67歳)を対象とした。Ho:YAGレーザーを2.5W、0.5Jの条件下に、局所麻酔後、病変部表面粘膜が白色に変化するまで非接触下に焼灼した。病変が深部におよびレーザー光の到達が困難な症例や、表面焼灼後、内部に液体成分の残留を触知した症例では、外焼灼と併用して組織内焼灼を行う複合焼灼法を施行した。37例全例で、術中・術後に異常出血や知覚障害、機能障害は認めず、34例で完治が得られた。大きさは3mmから30mm程度のものがあり、複数個あるものが6症例であった。そのうちの3例には再発を認め、2例については再焼灼を行い治癒が得られた。残りの1例に関しては、再焼灼を提示するも患者本人が希望せず経過観察を行っている。Ho:YAGレーザーによる静脈奇形の治療方法は、機能や知覚の温存が可能でかつ特別な止血や縫合処置も必要としないため、形態を損なわず審美的な面からもきわめて有用であると考えられた。

researchmap

Authorship：Lead author   Language：Japanese   Publisher：日本口腔組織培養学会  

researchmap

Language：Japanese   Publisher：千葉医学会  

researchmap

Language：Japanese   Publisher：(一社)日本口腔ケア学会  

J-GLOBAL

researchmap

Language：English   Publisher：(一社)日本癌学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

J-GLOBAL

researchmap

Language：Japanese   Publisher：(一社)日本有病者歯科医療学会  

researchmap

Language：Japanese   Publisher：(一社)栃木県歯科医師会  

当科における感染性心内膜炎(IE)発症リスク患者の歯科処置内容について検討し、当院心臓・血管内科でのIE発症患者の血液培養から検出された菌種の変遷について検討した。歯科処置を実施したのは967症例(男性567例、女性400例、平均67.5歳)であった。処置内容は抜歯(927例)、スケーリング(801例)、抜糸(427例)の順で多く認められた。これらの処置に対し、経過が追跡できたすべての症例において、歯科処置後に明らかなIEの徴候は認めなかった。血液培養から検出された菌種について検討したのは76例であり、口腔内常在菌の代表菌種であるviridans group streptococciが前期(2000年1月〜2010年12月)では31例中17例(54.8%)、後期(2011年1月〜2017年3月)では45例中17例(37.8%)に検出された。当院でIEと診断された患者で、血中から口腔内常在菌種が検出された症例は前期17/31(54.8%)に対し、後期17/45(37.8%)であった。またStaphylococcus aureusは前期4例に対し、後期は11例から検出された。

researchmap

Language：Japanese   Publisher：(一社)日本歯科薬物療法学会  

researchmap

Language：Japanese   Publisher：千葉医学会  

researchmap

Language：Japanese   Publisher：(一社)栃木県歯科医師会  

口腔ケアの取り組みの効果判定のひとつとして、当院で実施された血液培養の結果の変遷に着目し検討を行った。2006年1月から2015年6月までの9年5ヵ月間に当院25科で実施された血液培養66277症例のうち、陽性となった10413症例を対象とした。血液培養陽性数は、検体数の増加とは比例することはなく、年平均約16%前後の陽性率で推移していた。検出きれた菌グループの割合は、腸内細菌が25%、非発酵菌が8%、グラム陽性球菌が49%、いわゆる嫌気性菌が3%、真菌が4%、その他が11%であった。また、口腔ケア外来初診患者数と口腔ケアリンクナース認定者数は、経年的に増加傾向を示していた。グラム陽性球菌の検出率と口腔ケア外来初診患者数、リンクナース数は高い負の相関を示した。

researchmap

researchmap

Language：Japanese   Publisher：(NPO)日本口腔科学会  

researchmap

Language：Japanese   Publisher：(一社)栃木県歯科医師会  

39年間に一次治療を行った口腔扁平上皮癌495例(男性307例、女性188例、17〜98歳)を対象とした。発生部位別では、舌が231例、下顎歯肉が96例、上顎歯肉が65例、頬粘膜が42例、口底が36例、口蓋・軟口蓋が11例、口唇が9例、その他が5例であった。UICCのTNM分類細で分類し、T2症例が196例と最も多く、N分類ではN0症例が283例と最も多かった。全症例で診断時に遠隔転移は認めなかった。UICCのStage分類で分類し、Stage 0が9例、Stage Iが74例、Stage IIが124例、Stage IIIが82例、Stage IVが206例であった。組織学的悪性度は、高分化型303例、中分化型118例、低分化型46例であった。治療方法の内訳は、手術単独146例、手術+化学療法160例、手術+放射線療法27例、手術+放射線化学療法75例、化学療法のみ10例、放射線療法のみ39例、放射線化学療法38例であった。病期別5年生存率は、Stage Iで94.6%、Stage IIで85.0%、Stage IIIで72.9%、Stage IVで62.6%であった。

researchmap

Event date： 2020.10

Presentation type：Poster presentation  

researchmap

Event date： 2020.10

Presentation type：Poster presentation  

researchmap

Event date： 2017.4

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Poster presentation  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap

Presentation type：Oral presentation (general)  

researchmap